Fintel on MSN1d
Leerink Partners Downgrades Accolade (ACCD)Fintel reports that on January 8, 2025, Leerink Partners downgraded their outlook for Accolade (NasdaqGS:ACCD) from ...
Leerink Partners analyst Andrew Berens maintained a Hold rating on Agios Pharma (AGIO – Research Report) on January 6. The company’s shares ...
Hosted on MSN3d
Leerink Partners Upgrades Align Technology (ALGN)Fintel reports that on January 6, 2025, Leerink Partners upgraded their outlook for Align Technology (NasdaqGS:ALGN) from ...
Leerink Partners has recently reduced CureVac BV (CVAC) stock to Market Perform rating, as announced on April 25, 2024, according to Finviz. Earlier, on June 8, 2023, SVB Securities had initiated the ...
Stock analysts at Leerink Partnrs decreased their Q4 2025 earnings per share (EPS) estimates for Illumina in a note issued to ...
On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors ...
Equities researchers at Leerink Partnrs lifted their Q1 2025 earnings estimates for Illumina in a report released on Tuesday, ...
Leerink Partners analyst Puneet Souda has maintained their bullish stance on NTRA stock, giving a Buy rating on January 7.Stay Ahead of the ...
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 17.88% ...
Align Technology upgraded by Leerink Partners with a $280 price target, citing growth potential, stock buyback plans, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback